97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-019970-33-GB
(EUCTR)
01/02/201113/10/2010A multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitis - Ulcerative colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Code: KRP203A
Product Code: KRP203A
Product Code: KRP203A
Novartis Services AGNULLNot RecruitingFemale: yes
Male: yes
80Hungary;Germany;United Kingdom;Belgium;Sweden
2EUCTR2010-019970-33-DE
(EUCTR)
22/12/201015/10/2010A multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitis - Ulcerative colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Name: KRP203
Product Code: KRP203
Product Name: KRP203
Product Code: KRP203
Product Name: KRP203
Product Code: KRP203
Novartis Services AGNULLNot RecruitingFemale: yes
Male: yes
72Hungary;United Kingdom;Germany;Belgium;Sweden
3EUCTR2010-019970-33-BE
(EUCTR)
07/12/201020/09/2010A multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitisA multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitis Ulcerative colitis
MedDRA version: 14.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders
Product Code: KRP203A
Product Code: KRP203A
Product Code: KRP203A
Novartis Services AGNULLNot RecruitingFemale: yes
Male: yes
72Phase 2Hungary;Belgium;Germany;United Kingdom;Sweden
4NCT01375179
(ClinicalTrials.gov)
December 201012/5/2011Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis PatientsA Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative ColitisUlcerative ColitisDrug: KRP203;Drug: Placebo matching KRP203Novartis PharmaceuticalsNULLTerminated18 Years65 YearsAll27Phase 2Belgium;Germany;Hungary;Sweden;Switzerland;United Kingdom
5EUCTR2010-019970-33-HU
(EUCTR)
11/11/201007/09/2010A multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitis - Ulcerative colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Name: n.a.
Product Code: KRP203A
Product Name: n.a
Product Code: KRP203A
Product Name: n.a
Product Code: KRP203A
Novartis Services AGNULLNot RecruitingFemale: yes
Male: yes
72Hungary;Germany;United Kingdom;Belgium;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2010-019970-33-SE
(EUCTR)
29/10/201010/09/2010A multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitisA multi-centre, double-blind, placebo controlled, parallelgroup, proof of concept study to evaluate the efficacy,safety and tolerability of KRP203 in subjects withmoderately active refractory ulcerative colitis Ulcerative colitis
MedDRA version: 12.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Name: KRP203
Product Code: KRP203A
Product Name: KRP203
Product Code: KRP203A
Product Name: KRP203
Product Code: KRP203A
Novartis Services AGNULLNot RecruitingFemale: yes
Male: yes
72Hungary;Belgium;Germany;United Kingdom;Sweden